DataExpo GAKG DeepReport Navigation

Copyright©2015-2024 Acemap, Inc. Shanghai Jiao Tong University. All rights reserved.

沪ICP备18028330号

RA

R Arocho

Amgen (United States)

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Roman Casciano

Certara (United States)

Rafael Hurtado

Hospital Angeles Pedregal

Julian Casciano

Delray Medical Center

Steven R. Arikian

Genesis Medical Center

Josep Darbà

Universitat de Barcelona

Charlotte A. McMillan

Pfizer (United States)

Carlos Rubio-Terrés

Karolinska Institutet

Martina Lema

Complexo Hospitalario Universitario A Coruña

Marisa García de Paredes

Hospital Universitario Ramón y Cajal

Joan Maurel

Instituto de Salud Carlos III

Cooperative Institutions

Amgen (United States)

Pfizer (United States)

Health Economics and Outcomes Research (United Kingdom)

IQVIA (United States)

Universitat de Barcelona

Pfizer (Spain)

Columbia University

Mexican Social Security Institute

Pharmerit (United States)

Amgen (Switzerland)

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

A pharmacoeconomic evaluation of amlodipine usage in patients undergoing PTCA in the US using results from the Coronary Angioplasty Amlodipine Restenosis Study (CAPARES).

Erik Thaulow B Jørgensen Doyle Jj Roman Casciano Julian Casciano

Amlodipine

Cite

Citations (2)

PCN9 Economic Evaluation of Panitumumab vs Cetuximab in Patients with Colorectal Carcinoma (CRCM) with Non-Mutated (WILD-TYPE) Kras After Failure of Chemotherapy Regimens in Mexico

Value in Health (2011)

R Arocho Rafael Hurtado

Panitumumab

Public healthcare

10.1016/j.jval.2011.08.1570

Cite

Citations (1)

PCN6 PRIMARY PROPHYLAXIS WITH PEGFILGRASTIM IS COSTSAVING COMPARED WITH FILGRASTIM FOR BREAST CANCER IN SPAIN

Value in Health (2006)

J I Mayordomo Antonio López‐Pousa R Arocho QV Doan RW Dubois

Pegfilgrastim

10.1016/s1098-3015(10)63436-5

Cite

Citations (2)

Economic Benefits of Amlodipine Treatment in Patients with Coronary Artery Disease

PharmacoEconomics (2002)

Roman Casciano John Doyle John Chen Steve Arikian Julian Casciano

Amlodipine

10.2165/00019053-200220080-00005

Cite

Citations (5)

PCN22 COST-EFFECTIVENESS (CE) OF THE PREVENTION OF ORAL MUCOSITIS (OM) WITH KEPIVANCE® (PALIFERMIN) IN PATIENTS UNDERGOING MYELOABLATIVE THERAPY WITH AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN SPAIN

Value in Health (2006)

Max Brosa R Arocho

Mucositis

Autologous stem-cell transplantation

10.1016/s1098-3015(10)63452-3

Cite

Citations (2)

PSY7 Cost Of Managing Bleeding-Related Episodes (BRE) For Romiplostim Versus Standard Of Care (SOC) In Patients With Chronic Immune Thrombocytopenia (ITP) In Mexico

Value in Health (2011)

R Arocho Kelly Northridge Rafael Hurtado Janny Guzman Chavez

ITP, an autoimmune disorder characterized by isolated thrombocytopenia, puts patients at risk of BRE, the management of which can pose a high economic burden. The novel TPO-mimetic romiplostim is recommended for treatment of adult patients with chronic ITP. We compared BRE rates, and the costs of managing BRE in Mexico, for romiplostim versus SOC in adult patients with chronic ITP. BRE rates were obtained from two randomized placebo-controlled trials in splenectomized and non-splenectomized patients. BRE were categorized as: outpatient minor bleed, bleed requiring immunoglobulin treatment, or bleeding-related hospitalizations. BRE costs were calculated by splenectomy status and treatment group, with unit costs obtained from the 2010 Official Price List of the Public Healthcare System in Mexico. The frequency of each BRE was multiplied by its managing cost and this total cost divided by the total number of patient-weeks in each treatment arm to obtain an average cost per patient per week. The average cost per patient per week was then extrapolated to the treatment duration of 52 weeks. The analysis included 62 non-splenectomized (41 romiplostim, 21 SOC) and 63 splenectomized patients (42 romiplostim, 21 SOC), with a total of 2,715 patient-weeks on study. Romiplostim yielded a 55% reduction in all BRE (95% CI: 41% to 65%) and an 88% (95% CI 80% to 93%) reduction in those requiring immunoglobulin treatment. The estimated yearly BRE management cost per non-splenectomized patient was MXP$33,103 for romiplostim and MXP$162,720 for SOC. The estimated yearly BRE management cost per splenectomized patient was MXP$31,328 for romiplostim and MXP$283,246 for SOC. Romiplostim is an important therapeutic alternative for adult patients with chronic ITP which reduces the incidence of BREs compared to SOC, and lowers BRE management costs for the Mexican Public Healthcare system.

Romiplostim

10.1016/j.jval.2011.08.1716

Cite

Citations (0)

PDD3: A COST-OF-TREATMENT MODEL FOR TYPE 2 DIABETES

Value in Health (1999)

JM Stephens MF Botteman Ramsdell Jw J A Grossman R Arocho

10.1016/s1098-3015(11)71005-1

Cite

Citations (1)

Evaluación económica del uso de pegfilgrastim frente a filgrastim en profilaxis primaria en pacientes con cáncer de mama con riesgo de padecer neutropenia febril en España

PharmacoEconomics Spanish Research Articles (2008)

José Ignacio Mayordomo Cámara Antonio López‐Pousa Emmanuel Giménez García Xavier Badia Llach Núria Lara Surinyach

Pegfilgrastim

10.1007/bf03320844

Cite

Citations (2)

PHM1 ASSESSING PATIENTS' RISKS OF BLOOD TRANSFUSIONS: A LITERATURE REVIEW OF PUBLISHED INCIDENCE RATES

Value in Health (2007)

Josep Darbà A Minoves R Arocho

10.1016/s1098-3015(10)65028-0

Cite

Citations (0)

Respuesta de los autores

PharmacoEconomics Spanish Research Articles (2010)

R Arocho Marisa García de Paredes Joan Maurel Martina Lema W. M. Hart

10.1007/bf03320868

Cite

Citations (0)